title: A neurokinin 1 receptor antagonist decreases postoperative peritoneal adhesion formation and increases peritoneal fibrinolytic activity.
abstract: Fibrous adhesions remain a major sequela of abdominal surgery. The proinflammatory peptide substance P (SP), known to participate in inflammatory events, may play a key role in adhesion formation. This hypothesis was tested by using an antagonist, CJ-12,255 (Pfizer), that blocks the binding of SP to the neurokinin 1 receptor (NK-1R). Adhesion formation was surgically induced in the peritoneum of rats receiving daily doses of the NK-1R antagonist (NK-1RA; 5.0 or 10.0 mg/kg per day) or saline. On postoperative day 7, both the low and high doses of NK-1RA significantly (P < 0.05) reduced adhesion formation by 45% and 53%, respectively, compared with controls. Subsequently, the effect of NK-1RA administration on peritoneal fibrinolytic activity was investigated to determine a potential mechanism for SP action in the peritoneum. Samples were collected from nonoperated controls and from animals 24 h postsurgery that were administered either NK-1RA or saline. Fibrinolytic activity in peritoneal fluid was assayed by zymography, and expression of tissue plasminogen activator (tPA) and plasminogen activator inhibitor 1, both regulators of fibrinolytic activity, was assessed in peritoneal tissue and fluid by RT-PCR and bioassay, respectively. NK-1RA administration led to a marked (P < 0.05) increase in tPA mRNA levels in peritoneal tissue compared with nonoperated and saline-administered animals. Likewise, NK-1RA administration significantly (P < 0.05) increased tPA in the peritoneal fluid. These data suggest that activation of the NK-1R promotes peritoneal adhesion formation by limiting fibrinolytic activity in the postoperative peritoneum, thus enabling fibrinous adhesions to persist.
authors.affiliation: Department of Surgery, Boston University School of Medicine, Boston, MA 02118, USA.
authors.forename: Karen L
authors.initials: KL
authors.lastname: Reed
authors.forename: A Brent
authors.initials: AB
authors.lastname: Fruin
authors.forename: Adam C
authors.initials: AC
authors.lastname: Gower
authors.forename: Arthur F
authors.initials: AF
authors.lastname: Stucchi
authors.forename: Susan E
authors.initials: SE
authors.lastname: Leeman
authors.forename: James M
authors.initials: JM
authors.lastname: Becker
mesh_terms: D000818:Animals; D019086:Bridged Bicyclo Compounds, Heterocyclic / Q000494:pharmacology*; D005342:Fibrinolysis / Q000187:drug effects*; D015870:Gene Expression / Q000187:drug effects; D008297:Male; D064729:Neurokinin-1 Receptor Antagonists; D010532:Peritoneal Diseases / Q000378:metabolism / Q000517:prevention & control*; D010537:Peritoneum / Q000601:surgery; D011183:Postoperative Complications / Q000517:prevention & control*; D012333:RNA, Messenger / Q000096:biosynthesis; D051381:Rats; D017208:Rats, Wistar; D000267:Tissue Adhesions / Q000378:metabolism / Q000517:prevention & control*; D010959:Tissue Plasminogen Activator / Q000378:metabolism
chemical_list: C480026:6-diphenylmethyl-5-(5-isopropyl-2-methoxybenzylamino)-1-azabicyclo(2.2.2)octane-3-carboxylic acid; D019086:Bridged Bicyclo Compounds, Heterocyclic; D064729:Neurokinin-1 Receptor Antagonists; D012333:RNA, Messenger; D010959:Tissue Plasminogen Activator